SI-BONE, Inc. announced a 14.5% increase in worldwide revenue to $55.7 million for Q3 2026, driven by nearly 20% growth in U.S. procedure volumes. The company improved its net loss by 20.7% to $3.6 million and achieved positive adjusted EBITDA of $3.0 million. Key operational highlights include FDA clearance for the iFuse Granite Onyx device and favorable reimbursement changes boosting hospital payments. SI-BONE reaffirmed its 2026 revenue guidance and expects continued growth into 2027 with an expanded market opportunity.
SI-BONE, Inc. reported strong Q3 2026 results with a 14.5% revenue increase to $55.7 million. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 03, 2026 04:11 WIB: out of 150 priced US health stocks, 48 rose and 100 fell. Notable movers include HIMS at USD 25.22 (-8.89%), TVTX at USD 46.00 (-8.71%), and NTRA at USD 379.01 (-8.49%).
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
The FDA placed Bright Minds Biosciences' planned Phase 2 epilepsy trial for BMB-101 on partial clinical hold due to toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. This action caused a sharp decline in the compa...
NVIDIA has published detailed implementation recipes for its Cosmos world models, enabling developers to create simulations for vehicles, robots, and surgical procedures. These recipes guide model adaptation, testing, and GPU deployment, supporting v...
